Avidity Biosciences, Inc

Avidity Biosciences — Technical Presentation (June 2024)

47 slides from Avidity Biosciences's technical presentation, Jun 12, 2024

  1. Slide 1: Transforming FSHD: AOC 1020 FORTITUDE Phase 1/2 Initial Data

    1 June 12, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 9 Transforming Facioscapulohumeral Muscular Dystrophy (FSHD) AOC 1020 FORTITUDETM Phase 1/2 Initial Data

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking state

  3. Slide 3: Our Vision

    3 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Amy Living with FSHD

  4. Slide 4: Revolutionizing New Class of Targeted RNA Therapeutics

    4 Revolutionizing New Class of Targeted RNA Therapeutics AOC platform delivers reproducible, consistent data across muscle disease programs Rare Muscle Disease Therapies in Development Clinical Program Safety & Tolerability Delivery to Muscle Target Engagement Functional Improvement Facioscapulohume

  5. Slide 5: Purpose of Update

    5 Purpose of Update Present Initial Data from Phase 1/2 FORTITUDE Del-brax 2 mg/kg at 4 months • Unprecedented and consistent reduction in DUX4- regulated genes • Signs of functional improvement: muscle strength; increased reachable workspace; positive patient and clinician reported outcomes • Favor

  6. Slide 6: Del-brax: Transforming the Treatment of FSHD

    6 Del-brax: Transforming the Treatment of FSHD ​First-in-class and best-in-clas​s: greater than 50% reduction in DUX4 regulated genes Accelerating Del-brax Toward Approval Unprecedented & Consistent Reduction in DUX4 Regulated Genes Signs of Functional Improvement and Reported Outcomes Favorable Saf

  7. Slide 7: Avidity Management Team and Guest Speaker

    7 Jeffrey M. Statland, M.D. Professor of Neurology, University of Kansas Medical Center Steve Hughes, M.D. Chief Medical Officer Sarah Boyce President & CEO W. Michael Flanagan, Ph.D. Chief Scientific & Technical Officer Geoff Grande, CFA VP, Investor Relations & Corporate Communications Transformin

  8. Slide 8: Agenda/Outline

    8 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Delivering for People Living with FSHD Steve Hughes, M.D., CMO Leading the Field: Directly Targeting DUX4 Michael Flanagan, Ph.D., CSO & CTO FORTITUDETM Preliminary Data Assessment Jeffrey M. Statland, M.D., Professor

  9. Slide 9: Facioscapulohumeral Muscular Dystrophy (FSHD)

    9 Facioscapulohumeral Muscular Dystrophy (FSHD) Rare, hereditary disorder causing relentless loss of muscle function and progressive disability • One of the most common forms of muscular dystrophy • FSHD causes progressive muscle weakness, pain, fatigue and disability • Onset typically occurs in tee

  10. Slide 10: Phase 1/2 FORTITUDE Trial

    10 Phase 1/2 FORTITUDE Trial Initial data presented today from 2 mg/kg cohort at 4 months • Pharmacodynamics • Biomarkers • Measures of clinical activity • Muscle strength • Muscle function • Muscle composition (MRI) • Patient and Clinician reported outcomes Key Exploratory Objectives • Randomized,

  11. Slide 11: Baseline Demographics Generally Well Matched Between Groups

    11 Baseline Demographics Generally Well Matched Between Groups Cohort A Placebo N=4 % or mean (SD) Del-brax 2 mg/kg* N=8 % or mean (SD) Sex, % Male 75 62.5 Age, years 53.5 (10.15) 51.6 (11.62) Genetic Diagnosis, % FSHD 1 100 100 FSHD Clinical Score 9.3 (1.71) 9.3 (2.31) D4Z4 Repeat Number 5.0 (2.45)

  12. Slide 12: Del-brax: Favorable Safety and Tolerability

    12 Del-brax: Favorable Safety and Tolerability Subjects with ≥ 1 AE n (%) Placebo N=13 2 mg/kg* N=8 4 mg/kg N=18 Any AE 11 (84.6%) 8 (100%) 17 (94.4%) Related to study drug 3 (23.1%) 4 (50%) 9 (50%) Severe AE 0 0 0 Serious AE (SAE) 0 0 0 AE leading to study discontinuation 0 0 0 AE leading to death

  13. Slide 13: Accelerating Del-brax Registrational Plan

    13 Accelerating Del-brax Registrational Plan Pulling forward registrational cohorts Dose Booster Muscle biopsies to be performed at Baseline and 4 monthsMultidose quarterly with 1 booster after first 6 weeks; Dose listed is siRNA * Participants receive a first dose of 1mg/kg and then receive the 2mg

  14. Slide 14: Agenda/Outline

    14 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Delivering for People Living with FSHD Steve Hughes, M.D., CMO Leading the Field: Directly Targeting DUX4 Michael Flanagan, Ph.D., CSO & CTO FORTITUDETM Preliminary Data Assessment Jeffrey M. Statland, M.D., Professor

  15. Slide 15: Del-brax: Transforming the Treatment of FSHD

    15 Del-brax: Transforming the Treatment of FSHD Connecting the dots from delivery to function Delivery to Muscle Reduction in DUX4 Gene Signature Impact on FSHD Disease Biology Decrease in Novel Circulating Biomarker • Consistent and effective delivery of siRNA to muscle • Reinforcing the disruptive

  16. Slide 16: Del-brax: Targets DUX4, the Root Cause of FSHD

    16 Del-brax: Targets DUX4, the Root Cause of FSHD Targets aberrant expression of DUX4 mRNA for destruction FSHD disease pathology1,2 Del-brax Therapeutic Hypothesis 1 Lemmers RJLF, et al. Science 329:1650–1653 (2010) 2 Snider L, et al. PLoS Genet. 2010;6(10):e1001181;

  17. Slide 17: Consistent and Effective Delivery of siRNA to Muscle

    17 Del-brax: Consistent and Effective Delivery of siRNA to Muscle 1,2 mg/kg 0.1 1 10 si R N A M us cl e C on c. (n M ) n=7 2 mg/kg* Muscle biopsies were collected in leg muscles (vastus lateralis, vastus medialis, tibialis anterior, gastrocnemius medialis or gastrocnemius lateralis) with fat fractio

  18. Slide 18: DUX4-Regulated Genes Selected for Robustness and Reproducibility

    18 DUX4-Regulated Genes Selected for Robustness and Reproducibility Procured muscle biopsies, RNA sequencing, patient-derived cells informed the panel LEUTX TRIM43 KHDC1L MBD3L2 Avidity Gene Panel Validated qPCR assay RNA sequencing from healthy muscle biopsies RNA sequencing from FSHD muscle biopsi

  19. Slide 19: Del-brax Demonstrates Meaningful 53% Reduction in DUX4-regulated Genes

    19 Del-brax Demonstrates Meaningful 53% Reduction in DUX4-regulated Genes All del-brax treated participants showed reductions >20% in DUX4 regulated genes 41-Gene Panel3 ReDux4 Panel2 53% (12 mg/kg) • All del-brax treated participants showed greater than 20% reduction in DUX4 regulated genes • All

  20. Slide 20: Consistent >50% Reductions in DUX4-regulated Genes Across Panels

    20 -100 -75 -50 -25 0 D U X4 s co re * (% C ha ng e fr om B as el in e) PBO AOC 1020 (1 & 2 mg/kg) -100 -75 -50 -25 0 D U X4 s co re * (% C ha ng e fr om B as el in e) PBO AOC 1020 (1 & 2 mg/kg) -100 -75 -50 -25 0 D U X4 s co re * (% C ha ng e fr om B as el in e) PBO AOC 1020 (1 & 2 mg/kg) Del-brax

  21. Slide 21: Del-brax Impacts Underlying FSHD Disease Biology

    21 Del-brax Impacts Underlying FSHD Disease Biology Broad biological effects following del-brax treatment Dux4 Differential gene expression (excluding DUX4 regulated genes) in muscle utilizing RNASeq. N=7 del-brax 1 mg/kg (D1), 2 mg/kg (D43 and D92). One participant missed post-dose biopsy. Each col

  22. Slide 22: Circulating Biomarkers Provide Early Detection of Whole-Body Response

    22 Circulating Biomarkers Provide Early Detection of Whole-Body Response to Del-brax Treatment • Sampling of single muscle • Limited timepoints • Invasive • Comprehensive assessment throughout body • Continuous monitoring • Patient friendly Muscle Biopsy Circulating Biomarker

  23. Slide 23: Novel DUX4-Regulated Circulating Biomarker

    23 Advisors & Disease Expertise FSHD & Healthy Biopsies Plasma from FSHD & Healthy Volunteers Novel DUX4-Regulated Circulating Biomarker Potential accelerated approval endpoint Potential Accelerated Approval Endpoint • Significantly elevated in patients with FSHD as compared to healthy individuals •

  24. Slide 24: Early and Sustained Reduction of Novel Circulating Biomarker

    24 Del-brax Shows Early and Sustained Reduction of a Novel DUX4-Regulated Circulating Biomarker Del-brax treatment shows 25% reduction in circulating biomarker in participants with FSHD versus placebo PBO del-brax 2 mg/kg* 0 1 2 3 4 -40 -20 0 20 Study Month % C ha ng e fro m B as el in e AOC 1020 (1

  25. Slide 25: Decrease in Novel and Creatine Kinase Circulating Biomarkers

    25 Consistent and Confirmatory Decrease in Both Novel and Creatine Kinase Circulating Biomarkers Decreases in creatine kinase, an indicator of muscle damage 0 1 2 3 4 -40 -20 0 20 Study Month % C ha ng e fr om B as el in e AOC 1020 (1 & 2 mg/kg) PBO Novel DUX4-regulated biomarker Creatine kinase bio

  26. Slide 26: Del-brax: Transforming the Treatment of FSHD

    26 Del-brax: Transforming the Treatment of FSHD Connecting the dots from delivery to function Delivery to Muscle Reduction in DUX4 Gene Signature Impact on FSHD Disease Biology Decrease in Novel Circulating Biomarker • Consistent and effective delivery of siRNA to muscle • Reinforcing the disruptive

  27. Slide 27: Agenda/Outline

    27 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Delivering for People Living with FSHD Steve Hughes, M.D., CMO Leading the Field: Directly Targeting DUX4 Michael Flanagan, Ph.D., CSO & CTO FORTITUDETM Preliminary Data Assessment Jeffrey M. Statland, M.D., Professor

  28. Slide 28: Jeffrey M. Statland, M.D. Biography

    28 Jeffrey M. Statland, M.D. is a Professor of Neurology at the University of Kansas Medical Center in Kansas City, Kansas. His research background has centered primarily on describing the natural history of and response to therapy for neuromuscular diseases. He completed a neuromuscular fellowship

  29. Slide 29: Clinical Features of FSHD

    29 Rosenberg, R. N., & Pascual, J. M. (2020). Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease: Volume 2 . Huisinga J, et al. Muscle Nerve. 2018 Mar;57(3):503-506. doi: 10.1002/mus.25955. Epub 2017 Oct 6. PMID: 28877559; PMCID: PMC6631361. Clinical Features of FSHD • I

  30. Slide 30: FSHD Causes Progressive Muscle Weakness

    30 • Illustration shows typical early (pink) and later muscle involvement (blue) • Approximately 60% of adults presenting symptom is inability to reach above the shoulder height • The next most common presenting symptom in adults is foot drop • About 20% of individuals will lose the ability to walk

  31. Slide 31: Impact of Living with FSHD

    31 Impact of Living with FSHD n=1147 McNiff et al. J Neuromuscul Dis. 2024;11(2):459-472. General muscle weakness Difficulty using arms or hands Not being able to walk or impaired mobility Fatigue, energy and endurance Not having the energy to work or live as I want to Losing mobility/ability to wal

  32. Slide 32: Exploratory Endpoints: Muscle Strength, Range of Motion and Function, Reported Outcomes

    Exploratory Endpoints: Muscle Strength, Range of Motion and Function, Patient and Clinician Reported Outcomes

  33. Slide 33: Del-brax Improved Muscle Strength in Both Upper and Lower Limb

    33 Del-brax Improved Muscle Strength in Both Upper and Lower Limb ImprovingDeclining Placebo del-brax 2 mg/kg* Total Composite Ankle Dorsiflexion Shoulder Abductor -10 -5 0 5 -20 -10 0 10 -40 -20 0 20 Change from Baseline to Month 4 (Mean ± SEM) Percent Predicted Normal QMT by hand-held device Total

  34. Slide 34: Reachable Workspace: Validated Measurement of Upper Extremity Function

    34 Reachable Workspace (RWS): Validated Measurement of Quantifying Improvement in Upper Extremity Range of Motion and Function RWS correlates with ability to perform activities of daily living and maintain independence Video depicts healthy person demonstrating RWS Q1 Q3 Q2 Q4 Q3 Q4 Q5 Bioniks websi

  35. Slide 35: Del-brax Improved Reachable Workspace Compared to Placebo

    35 Del-brax Improved Reachable Workspace Compared to Placebo Improved range of motion and function; similar trends observed without weight Placebo del-brax 2 mg/kg* Q1 Q3 Q2 Q4 Q3 Q4 Q5 Change from Baseline to Month 4 (Mean ±SEM) Relative Surface Area Average n=8 & Dominant n=7 in the AOC group * Pa

  36. Slide 36: ReSolve Observational Study

    36 ReSolve (NCT03458832): 24 Months Observational Study • Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD (ReSolve) • FSHD Clinical Trial Research Network: at 11 centers in the US and EU • Goal: to hasten drug development for FSHD by validating new clinical outcome assessments

  37. Slide 37: Improved Reachable Workspace Compared to Matched Natural History Data

    37 Del-brax Improved Reachable Workspace Compared to Matched Natural History Data Reachable Workspace Q1-5; Dominant Arm; Weight: 500 g 2 mg/kg FORTITUDE (4 Mo) N=7^ RESOLVE Natural History (3 mo) N=63 ImprovingDeclining Natural history study del-brax 2 mg/kg* -0.025 0.000 0.025 0.050 0.075 Thanks t

  38. Slide 38: Positive Trends in Patient and Clinician Reported Outcome Measures

    38 Del-brax: Positive Trends Toward Improvement in Both Patient and Clinician Reported Outcome Measures CGI-C; CGI-S (Clinician Global Impression of Change; Severity) PGI-C; PGI-S (Patient Global Impression of Change; Severity) *first dose 1 mg/kg CGI-S CGI-C Clinician Reported Outcome Measures Chan

  39. Slide 39: Del-brax: Promising New Potential Treatment for Patients with FSHD

    39 Del-brax: Promising New Potential Treatment for Patients with FSHD • Effective muscle delivery with unprecedented and consistent >50% reduction in DUX4 regulated gene panels – impacting underlying FSHD disease biology • Decrease in circulating biomarkers (novel and creatine kinase) indicate whole

  40. Slide 40: Agenda/Outline

    40 Agenda/Outline Revolutionizing the Delivery of RNA Sarah Boyce, President & CEO Delivering for People Living with FSHD Steve Hughes, M.D., CMO Leading the Field: Directly Targeting DUX4 Michael Flanagan, Ph.D., CSO & CTO FORTITUDETM Preliminary Data Assessment Jeffrey M. Statland, M.D., Professor

  41. Slide 41: Del-brax: Transforming the Treatment of FSHD

    41 Del-brax: Transforming the Treatment of FSHD ​First-in-class and best-in-clas​s: greater than 50% reduction in DUX4 regulated genes Accelerating Del-brax Toward Approval Unprecedented & Consistent Reduction in DUX4 Regulated Genes Signs of Functional Improvement and Reported Outcomes Favorable Sa

  42. Slide 42: Delivering on the RNA Revolution

    42 Delivering on the RNA Revolution

  43. Slide 43: Delivering in 2024: Data Readouts in 3 Rare Diseases

    43 Delivering in 2024: 3 Data Readouts in 3 Clinical Programs in 3 Rare Diseases Del-desiran in DM1 >40,000 patients in U.S. MARINA-OLE data (Q1 2024) Initiation of global Phase 3 HARBOR trial (Q2 2024) Del-brax in FSHD ~16,000-38,000 patients in U.S. Phase 1/2 FORTITUDE initial data (Q2 2024) AOC 1

  44. Slide 44: Our Vision

    44 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Amy Living with FSHD

  45. Slide 45: Q&A

    45 June 12, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 9 Transforming Facioscapulohumeral Muscular Dystrophy (FSHD) AOC 1020 FORTITUDETM Phase 1/2 Initial Data Q&A

  46. Slide 46: Our Vision

    46 OUR VISION To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Amy Living with FSHD Amy Living with FSHD

  47. Slide 47: Transforming FSHD: AOC 1020 FORTITUDE Phase 1/2 Initial Data

    47 June 12, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 9 Transforming Facioscapulohumeral Muscular Dystrophy (FSHD) AOC 1020 FORTITUDETM Phase 1/2 Initial Data

Avidity Biosciences — Technical Presentation (June 2024) on 6ix